Table 2

Comparison of PRNT and ELISPOT-MNT using MAbs raised against recombinant DENV EDIII proteina

ImmunogenMAbIsotypeResultb
DENV-1DENV-2DENV-3DENV-4
PRNTELISPOT-MNTPRNTELISPOT-MNTPRNTELISPOT-MNTPRNTELISPOT-MNT
DENV-1 EDIII5E7A6IgG138.9113.963.3349.745.6349.6736.11>50
DENV-1 EDIII5A12A7IgG15.246.51>50>50>50>50>50>50
DENV-2 EDIII4C58A2IgG1>50>50>50>50>50>50>50>50
DENV-3 EDIII2D73A7IgG1>50>500.090.160.860.18>5018.82
DENV-3 EDIII4A19A2A33IgG1>50>502.017.874.0215.2>50>50
DENV-3 EDIII2D13A12IgG2b>50>5010.456.282.4410.31>50>50
DENV-4 EDIII1E1A7IgG136.8333.9>50>505.473.3843.8638.7
DENV-1-4 EDIII3E31A4IgG11.985.554.647.890.370.4137.7940.9
DENV-1-4 EDIII5E56A5IgG1>5013.96>50>502.0232.84>50>50
DENV-1-4 EDIII2B11A35IgG10.040.050.221.890.610.0240.993.91
  • a PRNT, plaque reduction neutralization test; ELISPOT-MNT, enzyme-linked immunospot based microneutralization test.

  • b The neutralization concentration for each MAbs was determined concurrently with two assay methods, and the data shown are the mean 50% inhibitory concentrations (IC50) (in μg/ml). “>50” indicates less than 50% inhibition at the highest MAb concentration of 50 μg/ml. All IC50 values were calculated by nonlinear, dose-response regression analysis with GraphPad Prism 5.04 software.